ArticleCancer medicine2026
Clinical and Echocardiographic Insights Into Right Heart Masses: A Retrospective Study in China (2010-2023).
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical and Echocardiographic Insights Into Right Heart Masses: A Retrospective Study in China (2010-2023).Cancer medicine · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to analyze the clinical and echocardiographic characteristics, pathological profiles, and outcomes of right heart masses, and to explore the role of echocardiography in the evaluation of these masses.
methodsWe retrospectively analyzed 171 patients with echocardiographically diagnosed and pathologically confirmed right heart masses from two centers (2010-2023). Data on clinical presentation, echocardiographic features, pathology, and follow-up were collected. Survival analysis using Kaplan-Meier curves and multivariable Cox regression was performed to identify prognostic factors.
resultsAmong 171 patients, 114 had primary cardiac tumors (82 benign, 30 malignant, and 2 of uncertain biological behavior), 41 had metastatic tumors, and 16 had thrombi or other lesions. Myxomas (63.4%) and angiosarcomas (63.3%) were the most common benign and malignant tumors, respectively. Patients with benign tumors had significantly better survival than those with malignant tumors, metastases, or thrombi (all p < 0.01). In the primary tumor subgroup (n = 112), better survival was associated with pedunculated morphology, well-defined margins, high mobility, and absence of metastasis (all p < 0.01). Multivariable analysis identified malignant tumor type (HR = 10.072, p < 0.001; reference: benign tumor), absence of a pedicle (HR = 2.610, p = 0.044; reference: presence of a pedicle), and presence of metastasis (HR = 3.210, p = 0.025; reference: no metastasis) as independent prognostic factors. The median follow-up was 26 months, with a recurrence rate of 4.7% and overall mortality of 35.7%.
conclusionTumor type, pedicle presence, and metastasis are key prognostic factors for primary right heart tumors. Echocardiography is essential for diagnosis and differential diagnosis of right heart masses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.